再鼎医药最新公布的研究数据显示,其研发的Zocilurtatug Pelitecan(简称Zoci)在小细胞肺癌伴脑转移患者中能够诱导快速且显著的颅内治疗反应。该药物同时在其他神经内分泌癌类型中也表现出令人期待的治疗活性。
再鼎医药最新公布的研究数据显示,其研发的Zocilurtatug Pelitecan(简称Zoci)在小细胞肺癌伴脑转移患者中能够诱导快速且显著的颅内治疗反应。该药物同时在其他神经内分泌癌类型中也表现出令人期待的治疗活性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.